This study investigates pancreatic cancer. It evaluates the use of an investigational vaccine in combination with Anti-PD1 therapy and chemotherapy as a postoperative treatment.
The study evaluates the safety and effectiveness of this treatment combination in patients who have undergone surgery for pancreatic cancer.
- Who can participate: Adults aged 18 to 75 years with pancreatic ductal adenocarcinoma who have had surgery and meet specific health criteria can participate. Participants must have adequate organ function and not have received certain treatments within two weeks prior to the study.
- Study details: Participants will receive an investigational vaccine along with Anti-PD1 therapy and chemotherapy.